Shares of Larimar Therapeutics, Inc. (NASDAQ:LRMR – Get Free Report) have been given a consensus recommendation of “Buy” by the eleven research firms that are presently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, seven have issued a buy recommendation and three have assigned a strong buy recommendation to the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $15.2857.
LRMR has been the subject of several research analyst reports. Truist Financial upgraded Larimar Therapeutics to a “strong-buy” rating in a report on Wednesday, March 25th. Lifesci Capital upgraded Larimar Therapeutics to a “strong-buy” rating in a report on Tuesday, February 24th. Wall Street Zen upgraded Larimar Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, May 16th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Larimar Therapeutics in a research report on Tuesday, April 21st. Finally, Wedbush cut their target price on Larimar Therapeutics from $13.00 to $12.00 and set an “outperform” rating on the stock in a research report on Monday, May 18th.
View Our Latest Report on LRMR
Larimar Therapeutics Stock Down 0.1%
Larimar Therapeutics (NASDAQ:LRMR – Get Free Report) last announced its quarterly earnings data on Thursday, May 14th. The company reported ($0.31) earnings per share for the quarter, beating the consensus estimate of ($0.53) by $0.22. Analysts anticipate that Larimar Therapeutics will post -1.66 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Larimar Therapeutics
Institutional investors and hedge funds have recently modified their holdings of the stock. BNP Paribas Financial Markets raised its position in shares of Larimar Therapeutics by 75.8% during the third quarter. BNP Paribas Financial Markets now owns 10,146 shares of the company’s stock worth $33,000 after purchasing an additional 4,376 shares during the period. Coldstream Capital Management Inc. acquired a new stake in shares of Larimar Therapeutics during the third quarter worth $57,000. SG Americas Securities LLC acquired a new stake in shares of Larimar Therapeutics during the fourth quarter worth $60,000. Sei Investments Co. raised its position in shares of Larimar Therapeutics by 54.5% during the first quarter. Sei Investments Co. now owns 16,336 shares of the company’s stock worth $74,000 after purchasing an additional 5,763 shares during the period. Finally, Commonwealth Equity Services LLC acquired a new stake in shares of Larimar Therapeutics during the fourth quarter worth $87,000. 91.92% of the stock is owned by institutional investors and hedge funds.
Larimar Therapeutics Company Profile
Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc is based in Bala Cynwyd, Pennsylvania.
Featured Articles
- Five stocks we like better than Larimar Therapeutics
- 3 Retail Winners Using Cash Flow to Stay Ahead
- 3 Tech ETFs That Could Bounce Back After the AI Selloff
- 3 Penny Stocks Under $5 Backed by Real Revenue Growth
- 3 Non-Pharma Firms That Could Benefit From the GLP-1 Trend
Receive News & Ratings for Larimar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Larimar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
